nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1A1—kidney cancer	0.16	0.653	CbGaD
Lansoprazole—MAPT—Paclitaxel—kidney cancer	0.149	0.302	CbGbCtD
Lansoprazole—ABCB1—kidney cancer	0.0851	0.347	CbGaD
Lansoprazole—CYP1B1—Erlotinib—kidney cancer	0.0258	0.0523	CbGbCtD
Lansoprazole—CYP1B1—Paclitaxel—kidney cancer	0.0236	0.0479	CbGbCtD
Lansoprazole—ABCG2—Pazopanib—kidney cancer	0.0172	0.0349	CbGbCtD
Lansoprazole—ABCG2—Dactinomycin—kidney cancer	0.0157	0.0319	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—kidney cancer	0.0127	0.0258	CbGbCtD
Lansoprazole—ABCG2—Erlotinib—kidney cancer	0.0122	0.0249	CbGbCtD
Lansoprazole—ABCB1—Temsirolimus—kidney cancer	0.0118	0.0239	CbGbCtD
Lansoprazole—CYP1A1—Erlotinib—kidney cancer	0.0113	0.023	CbGbCtD
Lansoprazole—ABCG2—Paclitaxel—kidney cancer	0.0112	0.0228	CbGbCtD
Lansoprazole—CYP2D6—Temsirolimus—kidney cancer	0.0111	0.0226	CbGbCtD
Lansoprazole—CYP3A4—Everolimus—kidney cancer	0.0104	0.0212	CbGbCtD
Lansoprazole—ABCG2—Sorafenib—kidney cancer	0.00996	0.0202	CbGbCtD
Lansoprazole—ABCG2—Vincristine—kidney cancer	0.00967	0.0196	CbGbCtD
Lansoprazole—CYP2C8—Pazopanib—kidney cancer	0.00914	0.0186	CbGbCtD
Lansoprazole—ABCG2—Sunitinib—kidney cancer	0.00807	0.0164	CbGbCtD
Lansoprazole—CYP1A2—Pazopanib—kidney cancer	0.00708	0.0144	CbGbCtD
Lansoprazole—CYP3A4—Temsirolimus—kidney cancer	0.00706	0.0143	CbGbCtD
Lansoprazole—CYP2C9—Capecitabine—kidney cancer	0.00665	0.0135	CbGbCtD
Lansoprazole—CYP2C8—Erlotinib—kidney cancer	0.00652	0.0133	CbGbCtD
Lansoprazole—ABCB1—Pazopanib—kidney cancer	0.00619	0.0126	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—kidney cancer	0.00604	0.0123	CbGbCtD
Lansoprazole—CYP2C8—Paclitaxel—kidney cancer	0.00597	0.0121	CbGbCtD
Lansoprazole—CYP2D6—Pazopanib—kidney cancer	0.00583	0.0118	CbGbCtD
Lansoprazole—ABCB1—Dactinomycin—kidney cancer	0.00566	0.0115	CbGbCtD
Lansoprazole—CYP2C8—Sorafenib—kidney cancer	0.0053	0.0108	CbGbCtD
Lansoprazole—CYP1A2—Erlotinib—kidney cancer	0.00505	0.0103	CbGbCtD
Lansoprazole—ABCB1—Gemcitabine—kidney cancer	0.00447	0.00909	CbGbCtD
Lansoprazole—CYP2C19—Sorafenib—kidney cancer	0.00445	0.00904	CbGbCtD
Lansoprazole—ABCB1—Erlotinib—kidney cancer	0.00442	0.00897	CbGbCtD
Lansoprazole—CYP2C9—Paclitaxel—kidney cancer	0.00417	0.00846	CbGbCtD
Lansoprazole—CYP2D6—Erlotinib—kidney cancer	0.00416	0.00845	CbGbCtD
Lansoprazole—CYP1A2—Sorafenib—kidney cancer	0.00411	0.00834	CbGbCtD
Lansoprazole—ABCB1—Paclitaxel—kidney cancer	0.00404	0.00821	CbGbCtD
Lansoprazole—CYP3A4—Pazopanib—kidney cancer	0.00371	0.00753	CbGbCtD
Lansoprazole—CYP2C9—Sorafenib—kidney cancer	0.0037	0.00752	CbGbCtD
Lansoprazole—ABCB1—Sorafenib—kidney cancer	0.00359	0.0073	CbGbCtD
Lansoprazole—ABCB1—Vinblastine—kidney cancer	0.00355	0.0072	CbGbCtD
Lansoprazole—ABCB1—Vincristine—kidney cancer	0.00349	0.00708	CbGbCtD
Lansoprazole—CYP2D6—Sorafenib—kidney cancer	0.00338	0.00687	CbGbCtD
Lansoprazole—CYP2D6—Vinblastine—kidney cancer	0.00334	0.00679	CbGbCtD
Lansoprazole—ABCB1—Sunitinib—kidney cancer	0.00291	0.00591	CbGbCtD
Lansoprazole—CYP3A4—Erlotinib—kidney cancer	0.00265	0.00538	CbGbCtD
Lansoprazole—CYP3A4—Paclitaxel—kidney cancer	0.00242	0.00492	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—kidney cancer	0.00218	0.00443	CbGbCtD
Lansoprazole—CYP3A4—Sorafenib—kidney cancer	0.00215	0.00437	CbGbCtD
Lansoprazole—CYP3A4—Vinblastine—kidney cancer	0.00212	0.00432	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—kidney cancer	0.00209	0.00424	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—kidney cancer	0.00205	0.00417	CbGbCtD
Lansoprazole—MAPT—nephron tubule—kidney cancer	0.00194	0.0772	CbGeAlD
Lansoprazole—CYP2C19—urine—kidney cancer	0.00187	0.0744	CbGeAlD
Lansoprazole—CYP3A4—Sunitinib—kidney cancer	0.00174	0.00354	CbGbCtD
Lansoprazole—MAPT—cortex of kidney—kidney cancer	0.00166	0.0661	CbGeAlD
Lansoprazole—CYP4A11—renal system—kidney cancer	0.00163	0.0646	CbGeAlD
Lansoprazole—CYP4A11—kidney—kidney cancer	0.00157	0.0625	CbGeAlD
Lansoprazole—CYP4A11—cortex of kidney—kidney cancer	0.00153	0.0609	CbGeAlD
Lansoprazole—CYP1A2—urine—kidney cancer	0.00153	0.0608	CbGeAlD
Lansoprazole—CYP2C9—urine—kidney cancer	0.00145	0.0577	CbGeAlD
Lansoprazole—Thiabendazole—CYP1A1—kidney cancer	0.00139	0.533	CrCbGaD
Lansoprazole—ATP4A—renal system—kidney cancer	0.00131	0.0521	CbGeAlD
Lansoprazole—CYP3A4—Doxorubicin—kidney cancer	0.00131	0.00265	CbGbCtD
Lansoprazole—ATP4A—kidney—kidney cancer	0.00127	0.0504	CbGeAlD
Lansoprazole—CYP3A4—urine—kidney cancer	0.00111	0.044	CbGeAlD
Lansoprazole—CYP2D6—urine—kidney cancer	0.00109	0.0433	CbGeAlD
Lansoprazole—CYP1B1—nephron tubule—kidney cancer	0.000574	0.0228	CbGeAlD
Lansoprazole—CYP1B1—renal system—kidney cancer	0.000522	0.0207	CbGeAlD
Lansoprazole—CYP1B1—kidney—kidney cancer	0.000505	0.0201	CbGeAlD
Lansoprazole—CYP1B1—cortex of kidney—kidney cancer	0.000491	0.0195	CbGeAlD
Lansoprazole—CYP1B1—gonad—kidney cancer	0.000468	0.0186	CbGeAlD
Lansoprazole—Rabeprazole—CYP1A1—kidney cancer	0.000439	0.168	CrCbGaD
Lansoprazole—ABCG2—nephron tubule—kidney cancer	0.000427	0.017	CbGeAlD
Lansoprazole—CYP2C8—renal system—kidney cancer	0.0004	0.0159	CbGeAlD
Lansoprazole—CYP2C8—kidney—kidney cancer	0.000386	0.0154	CbGeAlD
Lansoprazole—CYP1A2—renal system—kidney cancer	0.000374	0.0149	CbGeAlD
Lansoprazole—CYP1A1—renal system—kidney cancer	0.000369	0.0147	CbGeAlD
Lansoprazole—Omeprazole—CYP1A1—kidney cancer	0.000358	0.137	CrCbGaD
Lansoprazole—CYP1A1—kidney—kidney cancer	0.000357	0.0142	CbGeAlD
Lansoprazole—CYP1A1—cardiac atrium—kidney cancer	0.00033	0.0131	CbGeAlD
Lansoprazole—CYP3A4—renal system—kidney cancer	0.000271	0.0108	CbGeAlD
Lansoprazole—CYP2D6—renal system—kidney cancer	0.000266	0.0106	CbGeAlD
Lansoprazole—CYP3A4—kidney—kidney cancer	0.000262	0.0104	CbGeAlD
Lansoprazole—CYP2D6—kidney—kidney cancer	0.000258	0.0102	CbGeAlD
Lansoprazole—Pantoprazole—ABCB1—kidney cancer	0.000233	0.0892	CrCbGaD
Lansoprazole—ABCB1—nephron tubule—kidney cancer	0.000211	0.00838	CbGeAlD
Lansoprazole—ABCB1—renal system—kidney cancer	0.000192	0.00762	CbGeAlD
Lansoprazole—Omeprazole—ABCB1—kidney cancer	0.00019	0.0727	CrCbGaD
Lansoprazole—ABCB1—kidney—kidney cancer	0.000185	0.00736	CbGeAlD
Lansoprazole—ABCB1—cortex of kidney—kidney cancer	0.00018	0.00717	CbGeAlD
Lansoprazole—ABCB1—gonad—kidney cancer	0.000172	0.00683	CbGeAlD
Lansoprazole—Shock—Paclitaxel—kidney cancer	3.34e-05	0.000196	CcSEcCtD
Lansoprazole—Vomiting—Sorafenib—kidney cancer	3.34e-05	0.000196	CcSEcCtD
Lansoprazole—Nervous system disorder—Paclitaxel—kidney cancer	3.33e-05	0.000196	CcSEcCtD
Lansoprazole—Hypokalaemia—Doxorubicin—kidney cancer	3.33e-05	0.000195	CcSEcCtD
Lansoprazole—Thrombocytopenia—Paclitaxel—kidney cancer	3.33e-05	0.000195	CcSEcCtD
Lansoprazole—Tachycardia—Paclitaxel—kidney cancer	3.32e-05	0.000195	CcSEcCtD
Lansoprazole—Rash—Sorafenib—kidney cancer	3.31e-05	0.000195	CcSEcCtD
Lansoprazole—Dermatitis—Sorafenib—kidney cancer	3.31e-05	0.000194	CcSEcCtD
Lansoprazole—Back pain—Capecitabine—kidney cancer	3.31e-05	0.000194	CcSEcCtD
Lansoprazole—Breast disorder—Doxorubicin—kidney cancer	3.3e-05	0.000194	CcSEcCtD
Lansoprazole—Skin disorder—Paclitaxel—kidney cancer	3.3e-05	0.000194	CcSEcCtD
Lansoprazole—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	3.29e-05	0.000193	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	3.29e-05	0.000193	CcSEcCtD
Lansoprazole—Headache—Sorafenib—kidney cancer	3.29e-05	0.000193	CcSEcCtD
Lansoprazole—Muscle spasms—Capecitabine—kidney cancer	3.29e-05	0.000193	CcSEcCtD
Lansoprazole—Hyperhidrosis—Paclitaxel—kidney cancer	3.29e-05	0.000193	CcSEcCtD
Lansoprazole—Diarrhoea—Dactinomycin—kidney cancer	3.28e-05	0.000192	CcSEcCtD
Lansoprazole—Nasopharyngitis—Doxorubicin—kidney cancer	3.27e-05	0.000192	CcSEcCtD
Lansoprazole—Anorexia—Paclitaxel—kidney cancer	3.24e-05	0.00019	CcSEcCtD
Lansoprazole—Gastritis—Doxorubicin—kidney cancer	3.24e-05	0.00019	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Doxorubicin—kidney cancer	3.23e-05	0.000189	CcSEcCtD
Lansoprazole—Muscular weakness—Doxorubicin—kidney cancer	3.23e-05	0.000189	CcSEcCtD
Lansoprazole—Vision blurred—Capecitabine—kidney cancer	3.22e-05	0.000189	CcSEcCtD
Lansoprazole—Vomiting—Sunitinib—kidney cancer	3.22e-05	0.000189	CcSEcCtD
Lansoprazole—Body temperature increased—Gemcitabine—kidney cancer	3.21e-05	0.000188	CcSEcCtD
Lansoprazole—Tremor—Capecitabine—kidney cancer	3.2e-05	0.000188	CcSEcCtD
Lansoprazole—Rash—Sunitinib—kidney cancer	3.19e-05	0.000187	CcSEcCtD
Lansoprazole—Dermatitis—Sunitinib—kidney cancer	3.19e-05	0.000187	CcSEcCtD
Lansoprazole—Abdominal distension—Doxorubicin—kidney cancer	3.18e-05	0.000187	CcSEcCtD
Lansoprazole—Hypotension—Paclitaxel—kidney cancer	3.18e-05	0.000186	CcSEcCtD
Lansoprazole—Ill-defined disorder—Capecitabine—kidney cancer	3.17e-05	0.000186	CcSEcCtD
Lansoprazole—Headache—Sunitinib—kidney cancer	3.17e-05	0.000186	CcSEcCtD
Lansoprazole—Influenza—Doxorubicin—kidney cancer	3.16e-05	0.000186	CcSEcCtD
Lansoprazole—Asthma—Doxorubicin—kidney cancer	3.16e-05	0.000186	CcSEcCtD
Lansoprazole—Dysphagia—Doxorubicin—kidney cancer	3.16e-05	0.000186	CcSEcCtD
Lansoprazole—Anaemia—Capecitabine—kidney cancer	3.16e-05	0.000185	CcSEcCtD
Lansoprazole—Hypersensitivity—Vincristine—kidney cancer	3.15e-05	0.000185	CcSEcCtD
Lansoprazole—Eosinophilia—Doxorubicin—kidney cancer	3.13e-05	0.000184	CcSEcCtD
Lansoprazole—Nausea—Sorafenib—kidney cancer	3.12e-05	0.000183	CcSEcCtD
Lansoprazole—Pancreatitis—Doxorubicin—kidney cancer	3.1e-05	0.000182	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Paclitaxel—kidney cancer	3.1e-05	0.000182	CcSEcCtD
Lansoprazole—Malaise—Capecitabine—kidney cancer	3.08e-05	0.000181	CcSEcCtD
Lansoprazole—Angina pectoris—Doxorubicin—kidney cancer	3.08e-05	0.000181	CcSEcCtD
Lansoprazole—Insomnia—Paclitaxel—kidney cancer	3.07e-05	0.00018	CcSEcCtD
Lansoprazole—Vertigo—Capecitabine—kidney cancer	3.07e-05	0.00018	CcSEcCtD
Lansoprazole—Asthenia—Vincristine—kidney cancer	3.07e-05	0.00018	CcSEcCtD
Lansoprazole—Syncope—Capecitabine—kidney cancer	3.06e-05	0.00018	CcSEcCtD
Lansoprazole—Leukopenia—Capecitabine—kidney cancer	3.06e-05	0.000179	CcSEcCtD
Lansoprazole—Paraesthesia—Paclitaxel—kidney cancer	3.05e-05	0.000179	CcSEcCtD
Lansoprazole—Vomiting—Dactinomycin—kidney cancer	3.04e-05	0.000179	CcSEcCtD
Lansoprazole—Bronchitis—Doxorubicin—kidney cancer	3.04e-05	0.000178	CcSEcCtD
Lansoprazole—Dyspnoea—Paclitaxel—kidney cancer	3.03e-05	0.000178	CcSEcCtD
Lansoprazole—Somnolence—Paclitaxel—kidney cancer	3.02e-05	0.000177	CcSEcCtD
Lansoprazole—Palpitations—Capecitabine—kidney cancer	3.02e-05	0.000177	CcSEcCtD
Lansoprazole—Rash—Dactinomycin—kidney cancer	3.02e-05	0.000177	CcSEcCtD
Lansoprazole—Nausea—Sunitinib—kidney cancer	3e-05	0.000176	CcSEcCtD
Lansoprazole—Loss of consciousness—Capecitabine—kidney cancer	3e-05	0.000176	CcSEcCtD
Lansoprazole—Pancytopenia—Doxorubicin—kidney cancer	3e-05	0.000176	CcSEcCtD
Lansoprazole—Dyspepsia—Paclitaxel—kidney cancer	2.99e-05	0.000176	CcSEcCtD
Lansoprazole—Cough—Capecitabine—kidney cancer	2.98e-05	0.000175	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—kidney cancer	2.96e-05	0.000173	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—kidney cancer	2.96e-05	0.000173	CcSEcCtD
Lansoprazole—Decreased appetite—Paclitaxel—kidney cancer	2.95e-05	0.000173	CcSEcCtD
Lansoprazole—Hypertension—Capecitabine—kidney cancer	2.95e-05	0.000173	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—kidney cancer	2.94e-05	0.000172	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Paclitaxel—kidney cancer	2.93e-05	0.000172	CcSEcCtD
Lansoprazole—Fatigue—Paclitaxel—kidney cancer	2.93e-05	0.000172	CcSEcCtD
Lansoprazole—Diarrhoea—Vincristine—kidney cancer	2.93e-05	0.000172	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—kidney cancer	2.92e-05	0.000171	CcSEcCtD
Lansoprazole—Asthenia—Gemcitabine—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Chest pain—Capecitabine—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Arthralgia—Capecitabine—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Myalgia—Capecitabine—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Constipation—Paclitaxel—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Pain—Paclitaxel—kidney cancer	2.91e-05	0.000171	CcSEcCtD
Lansoprazole—Anxiety—Capecitabine—kidney cancer	2.9e-05	0.00017	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	2.89e-05	0.00017	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—kidney cancer	2.89e-05	0.000169	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—kidney cancer	2.88e-05	0.000169	CcSEcCtD
Lansoprazole—Discomfort—Capecitabine—kidney cancer	2.87e-05	0.000169	CcSEcCtD
Lansoprazole—Pruritus—Gemcitabine—kidney cancer	2.87e-05	0.000169	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—kidney cancer	2.85e-05	0.000167	CcSEcCtD
Lansoprazole—Dry mouth—Capecitabine—kidney cancer	2.84e-05	0.000167	CcSEcCtD
Lansoprazole—Nausea—Dactinomycin—kidney cancer	2.84e-05	0.000167	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—kidney cancer	2.83e-05	0.000166	CcSEcCtD
Lansoprazole—Dizziness—Vincristine—kidney cancer	2.83e-05	0.000166	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—kidney cancer	2.82e-05	0.000165	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—kidney cancer	2.82e-05	0.000165	CcSEcCtD
Lansoprazole—Confusional state—Capecitabine—kidney cancer	2.81e-05	0.000165	CcSEcCtD
Lansoprazole—Feeling abnormal—Paclitaxel—kidney cancer	2.8e-05	0.000164	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	2.79e-05	0.000164	CcSEcCtD
Lansoprazole—Oedema—Capecitabine—kidney cancer	2.79e-05	0.000164	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Paclitaxel—kidney cancer	2.78e-05	0.000163	CcSEcCtD
Lansoprazole—Diarrhoea—Gemcitabine—kidney cancer	2.78e-05	0.000163	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—kidney cancer	2.77e-05	0.000163	CcSEcCtD
Lansoprazole—Infection—Capecitabine—kidney cancer	2.77e-05	0.000163	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—kidney cancer	2.76e-05	0.000162	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—kidney cancer	2.75e-05	0.000161	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—kidney cancer	2.75e-05	0.000161	CcSEcCtD
Lansoprazole—Shock—Capecitabine—kidney cancer	2.74e-05	0.000161	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—kidney cancer	2.74e-05	0.000161	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—kidney cancer	2.74e-05	0.000161	CcSEcCtD
Lansoprazole—Nervous system disorder—Capecitabine—kidney cancer	2.73e-05	0.00016	CcSEcCtD
Lansoprazole—Thrombocytopenia—Capecitabine—kidney cancer	2.73e-05	0.00016	CcSEcCtD
Lansoprazole—Tachycardia—Capecitabine—kidney cancer	2.72e-05	0.00016	CcSEcCtD
Lansoprazole—Vomiting—Vincristine—kidney cancer	2.72e-05	0.00016	CcSEcCtD
Lansoprazole—Skin disorder—Capecitabine—kidney cancer	2.71e-05	0.000159	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—kidney cancer	2.7e-05	0.000159	CcSEcCtD
Lansoprazole—Urticaria—Paclitaxel—kidney cancer	2.7e-05	0.000158	CcSEcCtD
Lansoprazole—Rash—Vincristine—kidney cancer	2.7e-05	0.000158	CcSEcCtD
Lansoprazole—Hyperhidrosis—Capecitabine—kidney cancer	2.7e-05	0.000158	CcSEcCtD
Lansoprazole—Dermatitis—Vincristine—kidney cancer	2.7e-05	0.000158	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—kidney cancer	2.69e-05	0.000158	CcSEcCtD
Lansoprazole—Abdominal pain—Paclitaxel—kidney cancer	2.69e-05	0.000158	CcSEcCtD
Lansoprazole—Body temperature increased—Paclitaxel—kidney cancer	2.69e-05	0.000158	CcSEcCtD
Lansoprazole—Headache—Vincristine—kidney cancer	2.68e-05	0.000157	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—kidney cancer	2.67e-05	0.000156	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—kidney cancer	2.66e-05	0.000156	CcSEcCtD
Lansoprazole—Anorexia—Capecitabine—kidney cancer	2.66e-05	0.000156	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—kidney cancer	2.64e-05	0.000155	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—kidney cancer	2.63e-05	0.000154	CcSEcCtD
Lansoprazole—Hypotension—Capecitabine—kidney cancer	2.61e-05	0.000153	CcSEcCtD
Lansoprazole—Vomiting—Gemcitabine—kidney cancer	2.58e-05	0.000151	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—kidney cancer	2.58e-05	0.000151	CcSEcCtD
Lansoprazole—Rash—Gemcitabine—kidney cancer	2.56e-05	0.00015	CcSEcCtD
Lansoprazole—Dermatitis—Gemcitabine—kidney cancer	2.56e-05	0.00015	CcSEcCtD
Lansoprazole—Headache—Gemcitabine—kidney cancer	2.54e-05	0.000149	CcSEcCtD
Lansoprazole—Nausea—Vincristine—kidney cancer	2.54e-05	0.000149	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.54e-05	0.000149	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—kidney cancer	2.54e-05	0.000149	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—kidney cancer	2.53e-05	0.000148	CcSEcCtD
Lansoprazole—Insomnia—Capecitabine—kidney cancer	2.52e-05	0.000148	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—kidney cancer	2.52e-05	0.000148	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—kidney cancer	2.51e-05	0.000147	CcSEcCtD
Lansoprazole—Paraesthesia—Capecitabine—kidney cancer	2.5e-05	0.000147	CcSEcCtD
Lansoprazole—Hypersensitivity—Paclitaxel—kidney cancer	2.5e-05	0.000147	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—kidney cancer	2.5e-05	0.000147	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—kidney cancer	2.49e-05	0.000146	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—kidney cancer	2.49e-05	0.000146	CcSEcCtD
Lansoprazole—Dyspnoea—Capecitabine—kidney cancer	2.49e-05	0.000146	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—kidney cancer	2.48e-05	0.000146	CcSEcCtD
Lansoprazole—Dyspepsia—Capecitabine—kidney cancer	2.45e-05	0.000144	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—kidney cancer	2.44e-05	0.000143	CcSEcCtD
Lansoprazole—Asthenia—Paclitaxel—kidney cancer	2.44e-05	0.000143	CcSEcCtD
Lansoprazole—Decreased appetite—Capecitabine—kidney cancer	2.42e-05	0.000142	CcSEcCtD
Lansoprazole—Nausea—Gemcitabine—kidney cancer	2.41e-05	0.000141	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Capecitabine—kidney cancer	2.41e-05	0.000141	CcSEcCtD
Lansoprazole—Fatigue—Capecitabine—kidney cancer	2.4e-05	0.000141	CcSEcCtD
Lansoprazole—Pruritus—Paclitaxel—kidney cancer	2.4e-05	0.000141	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—kidney cancer	2.39e-05	0.00014	CcSEcCtD
Lansoprazole—Pain—Capecitabine—kidney cancer	2.38e-05	0.00014	CcSEcCtD
Lansoprazole—Constipation—Capecitabine—kidney cancer	2.38e-05	0.00014	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—kidney cancer	2.36e-05	0.000139	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—kidney cancer	2.36e-05	0.000138	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—kidney cancer	2.35e-05	0.000138	CcSEcCtD
Lansoprazole—Diarrhoea—Paclitaxel—kidney cancer	2.32e-05	0.000136	CcSEcCtD
Lansoprazole—Feeling abnormal—Capecitabine—kidney cancer	2.3e-05	0.000135	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—kidney cancer	2.3e-05	0.000135	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—kidney cancer	2.29e-05	0.000134	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Capecitabine—kidney cancer	2.28e-05	0.000134	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—kidney cancer	2.28e-05	0.000134	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—kidney cancer	2.27e-05	0.000133	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—kidney cancer	2.26e-05	0.000133	CcSEcCtD
Lansoprazole—Dizziness—Paclitaxel—kidney cancer	2.25e-05	0.000132	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—kidney cancer	2.24e-05	0.000131	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—kidney cancer	2.22e-05	0.00013	CcSEcCtD
Lansoprazole—Urticaria—Capecitabine—kidney cancer	2.22e-05	0.00013	CcSEcCtD
Lansoprazole—Abdominal pain—Capecitabine—kidney cancer	2.2e-05	0.000129	CcSEcCtD
Lansoprazole—Body temperature increased—Capecitabine—kidney cancer	2.2e-05	0.000129	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—kidney cancer	2.2e-05	0.000129	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—kidney cancer	2.2e-05	0.000129	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—kidney cancer	2.17e-05	0.000127	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—kidney cancer	2.16e-05	0.000127	CcSEcCtD
Lansoprazole—Vomiting—Paclitaxel—kidney cancer	2.16e-05	0.000127	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—kidney cancer	2.16e-05	0.000127	CcSEcCtD
Lansoprazole—Rash—Paclitaxel—kidney cancer	2.14e-05	0.000126	CcSEcCtD
Lansoprazole—Dermatitis—Paclitaxel—kidney cancer	2.14e-05	0.000126	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—kidney cancer	2.14e-05	0.000126	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—kidney cancer	2.13e-05	0.000125	CcSEcCtD
Lansoprazole—Headache—Paclitaxel—kidney cancer	2.13e-05	0.000125	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—kidney cancer	2.12e-05	0.000124	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—kidney cancer	2.08e-05	0.000122	CcSEcCtD
Lansoprazole—Hypersensitivity—Capecitabine—kidney cancer	2.05e-05	0.000121	CcSEcCtD
Lansoprazole—Ill-defined disorder—Doxorubicin—kidney cancer	2.04e-05	0.00012	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—kidney cancer	2.04e-05	0.000119	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—kidney cancer	2.02e-05	0.000119	CcSEcCtD
Lansoprazole—Nausea—Paclitaxel—kidney cancer	2.02e-05	0.000118	CcSEcCtD
Lansoprazole—Asthenia—Capecitabine—kidney cancer	2e-05	0.000117	CcSEcCtD
Lansoprazole—Malaise—Doxorubicin—kidney cancer	1.99e-05	0.000117	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—kidney cancer	1.98e-05	0.000116	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—kidney cancer	1.98e-05	0.000116	CcSEcCtD
Lansoprazole—Pruritus—Capecitabine—kidney cancer	1.97e-05	0.000116	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—kidney cancer	1.97e-05	0.000116	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—kidney cancer	1.95e-05	0.000114	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—kidney cancer	1.94e-05	0.000114	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—kidney cancer	1.92e-05	0.000113	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—kidney cancer	1.91e-05	0.000112	CcSEcCtD
Lansoprazole—Diarrhoea—Capecitabine—kidney cancer	1.91e-05	0.000112	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—kidney cancer	1.9e-05	0.000112	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—kidney cancer	1.88e-05	0.00011	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—kidney cancer	1.88e-05	0.00011	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—kidney cancer	1.88e-05	0.00011	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—kidney cancer	1.87e-05	0.00011	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.86e-05	0.000109	CcSEcCtD
Lansoprazole—Discomfort—Doxorubicin—kidney cancer	1.85e-05	0.000109	CcSEcCtD
Lansoprazole—Dizziness—Capecitabine—kidney cancer	1.84e-05	0.000108	CcSEcCtD
Lansoprazole—Dry mouth—Doxorubicin—kidney cancer	1.83e-05	0.000108	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—kidney cancer	1.81e-05	0.000106	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—kidney cancer	1.8e-05	0.000105	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—kidney cancer	1.8e-05	0.000105	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—kidney cancer	1.79e-05	0.000105	CcSEcCtD
Lansoprazole—Vomiting—Capecitabine—kidney cancer	1.77e-05	0.000104	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—kidney cancer	1.77e-05	0.000104	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—kidney cancer	1.76e-05	0.000103	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—kidney cancer	1.76e-05	0.000103	CcSEcCtD
Lansoprazole—Rash—Capecitabine—kidney cancer	1.76e-05	0.000103	CcSEcCtD
Lansoprazole—Dermatitis—Capecitabine—kidney cancer	1.76e-05	0.000103	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—kidney cancer	1.75e-05	0.000103	CcSEcCtD
Lansoprazole—Headache—Capecitabine—kidney cancer	1.75e-05	0.000103	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—kidney cancer	1.75e-05	0.000102	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—kidney cancer	1.74e-05	0.000102	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—kidney cancer	1.71e-05	0.000101	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—kidney cancer	1.68e-05	9.86e-05	CcSEcCtD
Lansoprazole—Nausea—Capecitabine—kidney cancer	1.66e-05	9.72e-05	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.64e-05	9.61e-05	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—kidney cancer	1.63e-05	9.54e-05	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—kidney cancer	1.61e-05	9.47e-05	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—kidney cancer	1.6e-05	9.41e-05	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—kidney cancer	1.6e-05	9.38e-05	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—kidney cancer	1.58e-05	9.29e-05	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—kidney cancer	1.56e-05	9.17e-05	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.55e-05	9.11e-05	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—kidney cancer	1.55e-05	9.1e-05	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—kidney cancer	1.54e-05	9.02e-05	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—kidney cancer	1.54e-05	9.02e-05	CcSEcCtD
Lansoprazole—Feeling abnormal—Doxorubicin—kidney cancer	1.48e-05	8.69e-05	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—kidney cancer	1.47e-05	8.63e-05	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—kidney cancer	1.43e-05	8.38e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Doxorubicin—kidney cancer	1.42e-05	8.34e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—kidney cancer	1.42e-05	8.34e-05	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—kidney cancer	1.32e-05	7.77e-05	CcSEcCtD
Lansoprazole—Asthenia—Doxorubicin—kidney cancer	1.29e-05	7.57e-05	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—kidney cancer	1.27e-05	7.46e-05	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—kidney cancer	1.23e-05	7.22e-05	CcSEcCtD
Lansoprazole—Dizziness—Doxorubicin—kidney cancer	1.19e-05	6.98e-05	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—kidney cancer	1.14e-05	6.71e-05	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—kidney cancer	1.13e-05	6.65e-05	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—kidney cancer	1.13e-05	6.65e-05	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—kidney cancer	1.13e-05	6.61e-05	CcSEcCtD
Lansoprazole—Nausea—Doxorubicin—kidney cancer	1.07e-05	6.27e-05	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—PGK1—kidney cancer	8.03e-06	0.000125	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC5A3—kidney cancer	8.03e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PDHB—kidney cancer	8.01e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ST3GAL2—kidney cancer	8.01e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—POMC—kidney cancer	7.99e-06	0.000124	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—BCHE—kidney cancer	7.93e-06	0.000123	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALDH1A1—kidney cancer	7.9e-06	0.000123	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—LDHB—kidney cancer	7.88e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—APRT—kidney cancer	7.87e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—FH—kidney cancer	7.87e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CA9—kidney cancer	7.84e-06	0.000122	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC5A5—kidney cancer	7.84e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALDH1A1—kidney cancer	7.83e-06	0.000121	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.71e-06	0.00012	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	7.69e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.66e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC5A3—kidney cancer	7.57e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PGK1—kidney cancer	7.57e-06	0.000117	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC2A1—kidney cancer	7.57e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CCBL1—kidney cancer	7.53e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PGK1—kidney cancer	7.51e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC5A3—kidney cancer	7.51e-06	0.000116	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	7.49e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—LDHB—kidney cancer	7.42e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GPC3—kidney cancer	7.4e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—LDHB—kidney cancer	7.36e-06	0.000114	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CRABP1—kidney cancer	7.27e-06	0.000113	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	7.22e-06	0.000112	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CA2—kidney cancer	7.2e-06	0.000112	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	7.09e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.04e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALAD—kidney cancer	7.01e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CA9—kidney cancer	7e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—POMC—kidney cancer	6.99e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GSTP1—kidney cancer	6.94e-06	0.000108	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	6.89e-06	0.000107	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ST3GAL2—kidney cancer	6.84e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.84e-06	0.000106	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CA9—kidney cancer	6.83e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ITPR2—kidney cancer	6.76e-06	0.000105	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	6.74e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALDH1A1—kidney cancer	6.69e-06	0.000104	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CRABP1—kidney cancer	6.67e-06	0.000103	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ABCB1—kidney cancer	6.57e-06	0.000102	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GLIPR1—kidney cancer	6.53e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPAT—kidney cancer	6.53e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CA9—kidney cancer	6.44e-06	9.99e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PGK1—kidney cancer	6.41e-06	9.95e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC5A3—kidney cancer	6.41e-06	9.95e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CA9—kidney cancer	6.38e-06	9.9e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GSTM1—kidney cancer	6.38e-06	9.89e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	6.37e-06	9.88e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSTP1—kidney cancer	6.31e-06	9.79e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—LDHB—kidney cancer	6.29e-06	9.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.24e-06	9.68e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.23e-06	9.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ITPR2—kidney cancer	6.2e-06	9.62e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ACHE—kidney cancer	6.17e-06	9.57e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTT1—kidney cancer	6.17e-06	9.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—POMC—kidney cancer	6.11e-06	9.49e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—APRT—kidney cancer	6.07e-06	9.42e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—FH—kidney cancer	6.07e-06	9.42e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP1A1—kidney cancer	6.04e-06	9.38e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ABCB1—kidney cancer	5.98e-06	9.27e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CRABP1—kidney cancer	5.95e-06	9.23e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	5.85e-06	9.08e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SCARB1—kidney cancer	5.84e-06	9.05e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CRABP1—kidney cancer	5.81e-06	9.01e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSTM1—kidney cancer	5.8e-06	9e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS1—kidney cancer	5.78e-06	8.96e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.71e-06	8.87e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GPC3—kidney cancer	5.71e-06	8.86e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PSMD7—kidney cancer	5.67e-06	8.79e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	5.66e-06	8.78e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTT1—kidney cancer	5.65e-06	8.77e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ACHE—kidney cancer	5.65e-06	8.77e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—kidney cancer	5.58e-06	8.66e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA2—kidney cancer	5.55e-06	8.62e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ITPR2—kidney cancer	5.53e-06	8.58e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP1A1—kidney cancer	5.5e-06	8.53e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CRABP1—kidney cancer	5.47e-06	8.49e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CA9—kidney cancer	5.45e-06	8.46e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CRABP1—kidney cancer	5.43e-06	8.42e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALAD—kidney cancer	5.41e-06	8.4e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ITPR2—kidney cancer	5.4e-06	8.38e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—BCHE—kidney cancer	5.37e-06	8.33e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SCARB1—kidney cancer	5.35e-06	8.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.33e-06	8.27e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC5A5—kidney cancer	5.31e-06	8.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS1—kidney cancer	5.3e-06	8.22e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ST3GAL2—kidney cancer	5.28e-06	8.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PSMD7—kidney cancer	5.19e-06	8.06e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALDH1A1—kidney cancer	5.16e-06	8.01e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC2A1—kidney cancer	5.12e-06	7.95e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.1e-06	7.91e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ITPR2—kidney cancer	5.09e-06	7.89e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTT1—kidney cancer	5.04e-06	7.83e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ACHE—kidney cancer	5.04e-06	7.83e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ITPR2—kidney cancer	5.04e-06	7.83e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.97e-06	7.71e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.97e-06	7.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC5A3—kidney cancer	4.95e-06	7.68e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PGK1—kidney cancer	4.95e-06	7.68e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ACHE—kidney cancer	4.92e-06	7.64e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTT1—kidney cancer	4.92e-06	7.64e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—BCHE—kidney cancer	4.92e-06	7.64e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—kidney cancer	4.88e-06	7.57e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTEN—kidney cancer	4.87e-06	7.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC5A5—kidney cancer	4.86e-06	7.55e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—LDHB—kidney cancer	4.85e-06	7.53e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SCARB1—kidney cancer	4.78e-06	7.41e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS1—kidney cancer	4.73e-06	7.33e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC2A1—kidney cancer	4.7e-06	7.29e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SCARB1—kidney cancer	4.66e-06	7.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.65e-06	7.22e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ACHE—kidney cancer	4.64e-06	7.2e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTT1—kidney cancer	4.64e-06	7.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CRABP1—kidney cancer	4.64e-06	7.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PSMD7—kidney cancer	4.64e-06	7.19e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS1—kidney cancer	4.61e-06	7.16e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ACHE—kidney cancer	4.6e-06	7.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTT1—kidney cancer	4.6e-06	7.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.56e-06	7.07e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PSMD7—kidney cancer	4.53e-06	7.02e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—POMC—kidney cancer	4.51e-06	6.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—BCHE—kidney cancer	4.39e-06	6.82e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SCARB1—kidney cancer	4.39e-06	6.81e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SCARB1—kidney cancer	4.35e-06	6.76e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS1—kidney cancer	4.35e-06	6.75e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC5A5—kidney cancer	4.34e-06	6.74e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.34e-06	6.73e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ITPR2—kidney cancer	4.31e-06	6.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS1—kidney cancer	4.31e-06	6.69e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—BCHE—kidney cancer	4.29e-06	6.66e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTP1—kidney cancer	4.27e-06	6.63e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PSMD7—kidney cancer	4.26e-06	6.62e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTEN—kidney cancer	4.25e-06	6.6e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC5A5—kidney cancer	4.24e-06	6.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PSMD7—kidney cancer	4.23e-06	6.56e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA9—kidney cancer	4.21e-06	6.53e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC2A1—kidney cancer	4.19e-06	6.51e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—POMC—kidney cancer	4.1e-06	6.36e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC2A1—kidney cancer	4.09e-06	6.35e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.07e-06	6.31e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—kidney cancer	4.05e-06	6.28e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—BCHE—kidney cancer	4.04e-06	6.27e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—BCHE—kidney cancer	4.01e-06	6.22e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.99e-06	6.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.97e-06	6.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.97e-06	6.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC5A5—kidney cancer	3.96e-06	6.14e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ACHE—kidney cancer	3.93e-06	6.1e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTT1—kidney cancer	3.93e-06	6.1e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTM1—kidney cancer	3.93e-06	6.09e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTP1—kidney cancer	3.92e-06	6.08e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.9e-06	6.05e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.86e-06	5.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.82e-06	5.93e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SCARB1—kidney cancer	3.72e-06	5.77e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.71e-06	5.75e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—kidney cancer	3.71e-06	5.75e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS1—kidney cancer	3.68e-06	5.72e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PSMD7—kidney cancer	3.61e-06	5.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTM1—kidney cancer	3.6e-06	5.59e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—kidney cancer	3.59e-06	5.58e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CRABP1—kidney cancer	3.58e-06	5.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.55e-06	5.5e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—kidney cancer	3.5e-06	5.43e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—kidney cancer	3.43e-06	5.33e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—BCHE—kidney cancer	3.42e-06	5.31e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—kidney cancer	3.41e-06	5.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP1A1—kidney cancer	3.41e-06	5.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC5A5—kidney cancer	3.38e-06	5.25e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ITPR2—kidney cancer	3.33e-06	5.16e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—kidney cancer	3.31e-06	5.14e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—kidney cancer	3.27e-06	5.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC2A1—kidney cancer	3.27e-06	5.07e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.23e-06	5.02e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—kidney cancer	3.22e-06	4.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTM1—kidney cancer	3.21e-06	4.99e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—kidney cancer	3.19e-06	4.95e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.17e-06	4.92e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTM1—kidney cancer	3.14e-06	4.87e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—kidney cancer	3.14e-06	4.86e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.06e-06	4.75e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.05e-06	4.73e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—kidney cancer	3.04e-06	4.72e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ACHE—kidney cancer	3.03e-06	4.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTT1—kidney cancer	3.03e-06	4.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—kidney cancer	3.02e-06	4.68e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—kidney cancer	3e-06	4.65e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP1A1—kidney cancer	2.97e-06	4.61e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTM1—kidney cancer	2.96e-06	4.59e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTM1—kidney cancer	2.93e-06	4.55e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SCARB1—kidney cancer	2.87e-06	4.46e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—kidney cancer	2.85e-06	4.43e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS1—kidney cancer	2.84e-06	4.41e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.8e-06	4.35e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.8e-06	4.35e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PSMD7—kidney cancer	2.79e-06	4.33e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.78e-06	4.31e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—POMC—kidney cancer	2.78e-06	4.31e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.76e-06	4.29e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—kidney cancer	2.72e-06	4.23e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—BCHE—kidney cancer	2.64e-06	4.1e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.61e-06	4.05e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—kidney cancer	2.58e-06	4e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—POMC—kidney cancer	2.54e-06	3.95e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.52e-06	3.91e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTM1—kidney cancer	2.5e-06	3.88e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.5e-06	3.88e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.37e-06	3.68e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.28e-06	3.54e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—POMC—kidney cancer	2.27e-06	3.52e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—POMC—kidney cancer	2.22e-06	3.44e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—kidney cancer	2.21e-06	3.43e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—kidney cancer	2.21e-06	3.43e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—kidney cancer	2.1e-06	3.26e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—POMC—kidney cancer	2.09e-06	3.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—POMC—kidney cancer	2.07e-06	3.21e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—kidney cancer	2.03e-06	3.15e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—kidney cancer	2.01e-06	3.12e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—kidney cancer	1.99e-06	3.09e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.95e-06	3.03e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTM1—kidney cancer	1.93e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—kidney cancer	1.93e-06	3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.83e-06	2.84e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—kidney cancer	1.81e-06	2.81e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—kidney cancer	1.77e-06	2.75e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—POMC—kidney cancer	1.77e-06	2.75e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—kidney cancer	1.77e-06	2.74e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—kidney cancer	1.67e-06	2.59e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—kidney cancer	1.65e-06	2.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—kidney cancer	1.58e-06	2.45e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—kidney cancer	1.54e-06	2.39e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—kidney cancer	1.45e-06	2.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—kidney cancer	1.44e-06	2.24e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—kidney cancer	1.41e-06	2.19e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—POMC—kidney cancer	1.37e-06	2.12e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.36e-06	2.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.25e-06	1.94e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—kidney cancer	1.23e-06	1.91e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.11e-06	1.73e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—kidney cancer	1.09e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—kidney cancer	1.09e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.03e-06	1.59e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.02e-06	1.58e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—kidney cancer	9.5e-07	1.47e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—kidney cancer	8.68e-07	1.35e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—kidney cancer	6.7e-07	1.04e-05	CbGpPWpGaD
